A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Qifangfeixian Granules in the Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD)
Clinical trial NCT06674148 · RECRUITING
Trial details
- NCT number
- NCT06674148
- Sponsor
- Huilan Zhang
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-25
- Primary completion
- 2027-05-20
- Enrollment
- 124
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.